Logo image of BGLC

BIONEXUS GENE LAB CORP (BGLC) Stock Price, Quote, News and Overview

NASDAQ:BGLC - Nasdaq - US0906282076 - Common Stock - Currency: USD

0.3513  +0.01 (+2.72%)

BGLC Quote, Performance and Key Statistics

BIONEXUS GENE LAB CORP

NASDAQ:BGLC (2/21/2025, 8:03:18 PM)

0.3513

+0.01 (+2.72%)

Sector
GICS SectorIndustrials
GICS IndustryTrading Companies & Distributors
GICS IndustryGroupCapital Goods
GICS SubIndustryTrading Companies & Distributors
Statistics
52 Week High1.2
52 Week Low0.21
Market Cap6.31M
Shares17.97M
Float10.11M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO03-11 2020-03-11


BGLC short term performance overview.The bars show the price performance of BGLC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

BGLC long term performance overview.The bars show the price performance of BGLC in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of BGLC is 0.3513 USD. In the past month the price increased by 2.03%. In the past year, price decreased by -48.35%.

BIONEXUS GENE LAB CORP / BGLC Daily stock chart

BGLC Competitors/Peers

The largest stocks on the US markets in the "Trading Companies & Distributors" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
GWW WW GRAINGER INC 25.87 49.08B
URI UNITED RENTALS INC 15.2 43.13B
FAST FASTENAL CO 37.2 42.88B
FERG FERGUSON ENTERPRISES INC 18.55 35.19B
WSO.B WATSCO INC -CL B 38.63 23.51B
WSO WATSCO INC 37.64 22.90B
AER AERCAP HOLDINGS NV 8.6 19.29B
FTAI FTAI AVIATION LTD 48.25 13.26B
CNM CORE & MAIN INC-CLASS A 22.06 10.13B
AIT APPLIED INDUSTRIAL TECH INC 24.89 9.43B
WCC WESCO INTERNATIONAL INC 14.95 8.98B
BECN BEACON ROOFING SUPPLY INC 16.11 7.22B

About BGLC

Company Profile

BGLC logo image BioNexus Gene Lab Corp. is a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2020-03-11. The firm provides a molecular lab that is focused on the application of functional genomics to enable early detection of infectious diseases and cancers. The firm operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex. MRNA Scientific Malaysia owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which the Company uses in its business. The firm's non-invasive blood screening tests analyze changes in RNA to coronavirus, dengue, human immunodeficiency virus (HIV), human papillomavirus (HPV) and the risk potentiality of cancer diseases. Chemrex is a wholesaler of industrial chemicals for the manufacture of industrial, medical, appliance, aero, automotive, mechanical and electronic industries in Asean region.

Company Info

BIONEXUS GENE LAB CORP

10-2 Tower B, Vertical Business Suite, 8 Jalan Kerinchi

KUALA LUMPUR WILAYAH PERSEKUTUAN MY

Employees: 9

Company Website: https://www.bionexusgenelab.com/

Investor Relations: http://www.bionexusgenelab.com/investor-relation

Phone: 13072416898

BIONEXUS GENE LAB CORP / BGLC FAQ

What is the stock price of BIONEXUS GENE LAB CORP today?

The current stock price of BGLC is 0.3513 USD. The price increased by 2.72% in the last trading session.


What is the ticker symbol for BIONEXUS GENE LAB CORP stock?

The exchange symbol of BIONEXUS GENE LAB CORP is BGLC and it is listed on the Nasdaq exchange.


On which exchange is BGLC stock listed?

BGLC stock is listed on the Nasdaq exchange.


What is BIONEXUS GENE LAB CORP worth?

BIONEXUS GENE LAB CORP (BGLC) has a market capitalization of 6.31M USD. This makes BGLC a Nano Cap stock.


How many employees does BIONEXUS GENE LAB CORP have?

BIONEXUS GENE LAB CORP (BGLC) currently has 9 employees.


What are the support and resistance levels for BIONEXUS GENE LAB CORP (BGLC) stock?

BIONEXUS GENE LAB CORP (BGLC) has a support level at 0.34 and a resistance level at 0.36. Check the full technical report for a detailed analysis of BGLC support and resistance levels.


Should I buy BIONEXUS GENE LAB CORP (BGLC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIONEXUS GENE LAB CORP (BGLC) stock pay dividends?

BGLC does not pay a dividend.


What is the Price/Earnings (PE) ratio of BIONEXUS GENE LAB CORP (BGLC)?

BIONEXUS GENE LAB CORP (BGLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).


What is the Short Interest ratio of BIONEXUS GENE LAB CORP (BGLC) stock?

The outstanding short interest for BIONEXUS GENE LAB CORP (BGLC) is 3.1% of its float. Check the ownership tab for more information on the BGLC short interest.


BGLC Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to BGLC. When comparing the yearly performance of all stocks, BGLC is a bad performer in the overall market: 80.47% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BGLC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BGLC. No worries on liquidiy or solvency for BGLC as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BGLC Financial Highlights

Over the last trailing twelve months BGLC reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 77.85% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -8.57%
ROE -10.04%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%48.92%
Sales Q2Q%3%
EPS 1Y (TTM)77.85%
Revenue 1Y (TTM)-10.48%

BGLC Ownership and Analysts


Ownership
Inst Owners0.99%
Ins Owners32.59%
Short Float %3.1%
Short Ratio0.07
Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A